Discovery and Basic Research
Seyoum Ayehunie, PhD
Chief Scientific Officer (CSO)
Mattek
Ashland, Massachusetts
Twinkle Christian
Principal Scientist
Amgen
Thousand Oaks, California
Lorna Ewart, PhD
Chief Scientific Officer
Emulate
Boston, Massachusetts
Annie Hamel, MSc (she/her/hers)
Scientific Director, Genetic Toxicology
Charles River Laboratories
Senneville, Quebec, Canada
James Gosset (he/him/his)
Associate Research Fellow
Pfizer Inc
Cambridge, Massachusetts
Regulatory agencies require a comprehensive evaluation of potential genotoxicity for all compounds intended to be administered to human or animals to identify substances that could cause carcinogenic effects by mutagenicity, clastogenicity or aneuploidy. To this day, there is no single preclinical genotoxicity test capable of detecting all mechanisms, and all assays involve an animal basis, such as the rodent metabolic activation system added to in vitro assays and in vivo rodents testing is mandatory, which could lead discrepancy from human accuracy. The objective of this work was to develop a humanized in vitro model capable of increasing human-relevant predictivity outcome and thus replacing animals testing. The developed model consists of a liver-on-chip co-cultured with human lymphoblastoid TK6 cells which is continuously perfused by media to mimic blood flow using a microphysiological fluidic system, from which all required genetic toxicology end points can be evaluated.